EUCTR2005-002814-39-AT进行中（未招募）不适用
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED,PLACEBO-CONTROLLED, TWO-ARM, PARALLEL-GROUP,SLEEP LAB TRIAL TO INVESTIGATE THE EFFICACY ANDSAFETY OF TRANSDERMAL ROTIGOTINE IN SUBJECTSWITH IDIOPATHIC RESTLESS LEGS SYNDROME
Schwarz Biosciences GmbH0 个研究点目标入组 60 人开始时间: 2005年10月4日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent.
- •2. Subject understands the investigational nature of the trial and is willing and able to comply
- •with the trial requirements. Subject is willing to accept that he/she might be treated with placebo during the treatment period.
- •3. Subject is able to apply/remove the trial patch correctly and consistently.
- •4. Subject is male or female, and is =18 and =75 years of age.
- •5. Subject meets the diagnosis of idiopathic RLS based on the 4 essential clinical features according to the IRLSSG (Allen et al, 2003):
- •a. An urge to move legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs (The urge to move can be present without uncomfortable
- •sensations. Arms or other body parts can also be affected.).
- •b. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.
- •c. The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.
- •d. The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night. (When symptoms are very severe, the worsening at night may not be noticeable but must have been previously present.).
- •6. Subject has had an initial response to previous dopaminergic treatment for RLS or has had no previous dopaminergic treatment (ie, de novo).
- •7. The subject’s body mass index (BMI) is =18kg/m2 and =35kg/m2.
- •8. At Baseline (Visit 2), subject has a score of =15 on the IRLS Rating Scale (indicating moderate to severe RLS).
- •9. At Baseline (Visit 2), subject scores =4 points on the CGI Item 1 assessment (indicating mildly ill).
- •10. At Baseline (Visit 2), subject scores =15 PLM/h on the PLMI based on PSG (recorded during the second night) as assessed by the investigator.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subject has secondary RLS (eg, due to renal insufficiency [uremia], iron deficiency anemia, or rheumatoid arthritis).
- •2. Subject has secondary RLS associated with previous or concomitant therapy with dopamine D2 receptor antagonists, butyrophenones, metoclopramide, atypical antipsychotics (eg, olanzapine), tri- and tetra-cyclic antidepressants, mianserine, lithium or H2-blockers (eg, cimetidine), or due to withdrawal from drugs such as anticonvulsants, benzodiazepines, barbiturates, and other hypnotics.
- •3. Subject has a history of sleep disturbances like sleep apnea syndrome (including obstructive sleep apnea), narcolepsy, sleep attacks/sudden onset of sleep, or myoclonus epilepsy either observed during PSG (local PSG evaluations) or evidenced by subject history.
- •4. Subject has additional clinically relevant concomitant diseases such as attention deficit hyperactivity disorder, polyneuropathy, akathisia, claudication, varicosis, muscle fasciculation, painful legs and moving toes, or radiculopathy.
- •5. Subject has other central nervous system diseases such as Parkinson’s disease, dementia, progressive supranuclear paresis, multisystem atrophy, Huntington’s Chorea, amyotrophic lateral sclerosis, or Alzheimer’s disease.
- •6. Subject has a prior history of psychotic episodes.
- •7. Subject has a history of chronic alcohol or drug abuse within the last 12 months.
- •8. Subject has any medical or psychiatric condition, which in the opinion of the investigator, can jeopardize or would compromise the subject’s ability to participate in this trial.
- •9. Subject has clinically relevant cardiac dysfunction and/or arrhythmias (eg, suspected conduction system dysregulations, second or third degree AV block, complete left or right bundle branch block, sick-sinus-syndrome, New York Heart Association Class III or IV congestive heart failure, or has had a myocardial infarction within 12 months prior to Screening [Visit 1]).
- •10. Subject has clinically relevant venous or arterial peripheral vascular disease.
- •11. Subject has clinically relevant renal dysfunction (serum creatinine >2.0mg/dL).
- •12. Subject has clinically relevant hepatic dysfunction (total bilirubin >2.0mg/dL or alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) greater than 2 times the upper limit of the reference range).
- •13. Subject has a malignant neoplastic disease requiring therapy within 12 months prior to Screening (Visit 1).
- •14. Subject is currently receiving treatment with any of the following drug classes: neuroleptics, hypnotics, antidepressants, anxiolytic drugs, anticonvulsive therapy, budipine, dopamine antagonist anti-emetics (except domperidone), opioids, benzodiazepines, monoamine oxidase (MAO) inhibitors, catechol-O-methyl-transferase (COMT) inhibitors, sedative antihistamines, psychostimulates, or amphetamines. If subject has received such therapy, a washout period of at least 7 days prior to Baseline (Visit 2) is required before starting treatment in this trial.
- •15. Subject is pregnant, nursing, or is a woman of child-bearing potential who is not surgically sterile, 2 years postmenopausal, or does not consistently use 2 combined effective methods of contraception, including at least 1 barrier method, unless sexually abstinent.
- •16. Subject pursues shift work or performs other continuous non-disease-related life conditions which do not allow regular sleep at night.
- •17. At Screening (Visit 1), subject has a QT interval in ECG, corrected for heart rate (QTc), in
研究者
相似试验
进行中（未招募）
不适用
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED,PLACEBO-CONTROLLED, TWO-ARM, PARALLEL-GROUP,SLEEP LAB TRIAL TO INVESTIGATE THE EFFICACY ANDSAFETY OF TRANSDERMAL ROTIGOTINE IN SUBJECTSWITH IDIOPATHIC RESTLESS LEGS SYNDROMEEUCTR2005-002814-39-FISchwarz Biosciences GmbH60
进行中（未招募）
不适用
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED,PLACEBO-CONTROLLED, TWO-ARM, PARALLEL-GROUP,SLEEP LAB TRIAL TO INVESTIGATE THE EFFICACY ANDSAFETY OF TRANSDERMAL ROTIGOTINE IN SUBJECTSWITH IDIOPATHIC RESTLESS LEGS SYNDROMEEUCTR2005-002814-39-DESchwarz Biosciences GmbH60
招募中
不适用
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TOEVALUATE THE EFFICACY AND SAFETY OFDAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITHMODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUSERYTHEMATOSUS-M32 Systemic lupus erythematosusM32Systemic lupus erythematosusPER-046-20CB Biopharma SRL,
招募中
3 期
Inebilizumab efficacy and safety in adults with myasthenia gravis2023-510006-40-00Horizon Therapeutics Ireland Designated Activity Company125
进行中（未招募）
1 期
Inebilizumab efficacy and safety in adults with myasthenia gravisMyasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK).MedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-000949-14-FRViela Bio, Inc.252